Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Metastatic Adenocarcinoma of The Pancreas Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Metastatic Adenocarcinoma of The Pancreas Overview | 11 | 1 |
| Pipeline Products for Metastatic Adenocarcinoma of The Pancreas Comparative Analysis | 12 | 1 |
| Metastatic Adenocarcinoma of The Pancreas Therapeutics under Development by Companies | 13 | 2 |
| Metastatic Adenocarcinoma of The Pancreas Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Metastatic Adenocarcinoma of The Pancreas Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Metastatic Adenocarcinoma of The Pancreas Products under Development by Companies | 19 | 2 |
| Metastatic Adenocarcinoma of The Pancreas Products under Investigation by Universities/Institutes | 21 | 1 |
| Metastatic Adenocarcinoma of The Pancreas Companies Involved in Therapeutics Development | 22 | 22 |
| AbbVie Inc | 22 | 1 |
| Aduro BioTech, Inc. | 23 | 1 |
| Array BioPharma Inc. | 24 | 1 |
| Axcentua Pharmaceuticals AB | 25 | 1 |
| Berg LLC | 26 | 1 |
| Boehringer Ingelheim GmbH | 27 | 1 |
| Boston Biomedical, Inc. | 28 | 1 |
| CTI BioPharma Corp. | 29 | 1 |
| CytRx Corporation | 30 | 1 |
| Daiichi Sankyo Company, Limited | 31 | 1 |
| Eleison Pharmaceuticals LLC | 32 | 1 |
| Gilead Sciences, Inc. | 33 | 1 |
| GlaxoSmithKline Plc | 34 | 1 |
| Incyte Corporation | 35 | 1 |
| MabVax Therapeutics Holdings, Inc. | 36 | 1 |
| Merrimack Pharmaceuticals, Inc. | 37 | 1 |
| NewLink Genetics Corporation | 38 | 1 |
| Novartis AG | 39 | 1 |
| Oncolytics Biotech Inc. | 40 | 1 |
| Pfizer Inc. | 41 | 1 |
| Phoenix Biotechnology, Inc. | 42 | 1 |
| Targovax ASA | 43 | 1 |
| Metastatic Adenocarcinoma of The Pancreas Therapeutics Assessment | 44 | 12 |
| Assessment by Monotherapy Products | 44 | 1 |
| Assessment by Combination Products | 45 | 1 |
| Assessment by Target | 46 | 3 |
| Assessment by Mechanism of Action | 49 | 3 |
| Assessment by Route of Administration | 52 | 2 |
| Assessment by Molecule Type | 54 | 2 |
| Drug Profiles | 56 | 152 |
| (curcumin + gemcitabine hydrochloride + paclitaxel) Drug Profile | 56 | 1 |
| aldoxorubicin hydrochloride Drug Profile | 57 | 14 |
| AXP-10711 Drug Profile | 71 | 2 |
| BI-853520 Drug Profile | 73 | 1 |
| binimetinib Drug Profile | 74 | 7 |
| Cellular Immunotherapy for Oncology Drug Profile | 81 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 82 | 1 |
| Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer Drug Profile | 83 | 2 |
| ceritinib Drug Profile | 85 | 5 |
| glufosfamide Drug Profile | 90 | 2 |
| GS-5745 Drug Profile | 92 | 2 |
| GSK-2256098 Drug Profile | 94 | 2 |
| HuMab-5B1 Drug Profile | 96 | 4 |
| ibrutinib Drug Profile | 100 | 25 |
| INCB-52793 Drug Profile | 125 | 1 |
| indoximod Drug Profile | 126 | 5 |
| irinotecan hydrochloride Drug Profile | 131 | 11 |
| MesoCART Drug Profile | 142 | 1 |
| Monoclonal Antibody Conjugate to Target Mesothelin for Oncology Drug Profile | 143 | 2 |
| napabucasin Drug Profile | 145 | 6 |
| nimotuzumab Drug Profile | 151 | 4 |
| palbociclib Drug Profile | 155 | 10 |
| PBI-05204 Drug Profile | 165 | 2 |
| pelareorep Drug Profile | 167 | 14 |
| PLX-7486 Drug Profile | 181 | 1 |
| PRI-724 Drug Profile | 182 | 2 |
| ribociclib succinate Drug Profile | 184 | 4 |
| SGT-53 Drug Profile | 188 | 2 |
| sonidegib phosphate Drug Profile | 190 | 5 |
| TG-01 Drug Profile | 195 | 3 |
| tosedostat Drug Profile | 198 | 5 |
| ubidecarenone Drug Profile | 203 | 3 |
| ulixertinib Drug Profile | 206 | 1 |
| Vaccine for Oncology Drug Profile | 207 | 1 |
| Metastatic Adenocarcinoma of The Pancreas Dormant Projects | 208 | 1 |
| Metastatic Adenocarcinoma of The Pancreas Discontinued Products | 209 | 1 |
| Metastatic Adenocarcinoma of The Pancreas Product Development Milestones | 210 | 6 |
| Featured News &Press Releases | 210 | 1 |
| Aug 04, 2016: Merrimack Provides Update on ONIVYDE | 210 | 1 |
| Jul 21, 2016: Baxalta receives CHMP positive opinion on Onivyde for the treatment of metastatic adenocarcinoma of the pancreas | 210 | 1 |
| Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer | 211 | 1 |
| May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 | 211 | 1 |
| Apr 14, 2016: Targovax reports immune response with reduced number of TG01 vaccinations | 212 | 1 |
| Jan 25, 2016: Boston Biomedical s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium | 212 | 2 |
| Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission | 214 | 1 |
| Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer | 215 | 1 |
| Appendix | 216 | 2 |
| Methodology | 216 | 1 |
| Coverage | 216 | 1 |
| Secondary Research | 216 | 1 |
| Primary Research | 216 | 1 |
| Expert Panel Validation | 216 | 1 |
| Contact Us | 216 | 1 |
| Disclaimer | 217 | 1 |